← 2026-10-21 edition · Sourced reporting
Published Oct 21, 2026, 7:30 AM Central · This version Oct 21, 2026, 7:30 AM Central · As of 2026-10-21
First generic Climara Pro patch approved; price and availability still need checking
FDA announced the first generic of the once-weekly combined Climara Pro patch, approved October 19. It is for specified uses in women with an intact uterus and carries important contraindications. Regulatory equivalence does not establish current stock, insurance coverage or a lower personal bill. [1] [2] [4] [5]
Use FDA’s exact product announcement when asking your prescriber or pharmacist about the combined patch, full current label, availability and coverage. Compare an actual refill quote before assuming savings or changing a prescription. →U.S. FDA October 20, 2026 announcement of an October 19 approval of the first generic Climara Pro combined estradiol–levonorgestrel patch. No individual medical advice, full label, price comparison, launch confirmation or recommendation to switch.
- 1 source record
- US Food and Drug Administration
Still open: Full current branded/generic labels, approval package, commercial launch, local stock, retail price and individual coverage not verified. All open questions ↓
Reporting question · As of 2026-10-21
The question: What changed with the first generic combined hormone patch, and what should patients verify?
U.S. FDA October 20, 2026 announcement of an October 19 approval of the first generic Climara Pro combined estradiol–levonorgestrel patch. No individual medical advice, full label, price comparison, launch confirmation or recommendation to switch.
What changed
First generic combined Climara Pro patch approved October 19; FDA announced it October 20.
[1]What needs clinical review
Specific indications for women with an intact uterus, plus important contraindications. Not interchangeable with every hormone patch.
[2] [3] [4]What needs an actual quote
Availability, pharmacy price and individual coverage. FDA does not establish them in this release.
[5]U.S. FDA announcement, October 20, 2026. Three checks with different purposes, not a treatment sequence, full safety label or measured price reduction.
Read the process as a table
| Component | Meaning | Evidence |
|---|---|---|
| What changed | First generic combined Climara Pro patch approved October 19; FDA announced it October 20. | [1] |
| What needs clinical review | Specific indications for women with an intact uterus, plus important contraindications. Not interchangeable with every hormone patch. | [2] [3] [4] |
| What needs an actual quote | Availability, pharmacy price and individual coverage. FDA does not establish them in this release. | [5] |
Archive photograph · 2009-05-20 · White Oak campus, Silver Spring, Maryland, United States
.jpg){kind=link}
.jpg#Licensing){kind=link}
Understand the story.
Approval and announcement are different dates
FDA’s October 20 release says it approved Zydus’s first generic Climara Pro patch the previous day. The patch combines estradiol and levonorgestrel and is applied weekly. The announcement describes therapeutic equivalence to Climara Pro; it does not announce a pharmacy’s stock or price. [1] [2] [5]
The combination matters
FDA limits the described uses to women with an intact uterus: treating moderate-to-severe menopausal vasomotor symptoms and preventing postmenopausal osteoporosis. This combined patch differs from estrogen-only patches. Its progestogen component addresses a specific endometrial risk; that does not erase other treatment risks. [2] [3]
Suitability comes before switching
The announcement lists important contraindications, including unexplained genital bleeding, breast-cancer history, estrogen-dependent cancers, clotting and arterial thromboembolic conditions, certain hypersensitivities, liver disease and inherited clotting disorders. This is a news summary, not the full label or a reason to change a prescription without clinical review. [4]
Check an actual refill offer
Ask the prescriber or pharmacist about the exact combined product, current prescribing information, substitution, availability and your coverage. FDA points availability questions to the manufacturer. No verified price comparison supports a claim that this approval already lowers any particular patient’s bill. [1] [2] [5]
How we know5 scoped claims · 1 source recordView evidence
Each claim keeps its full assertion, date, source passage and limits. Source counts describe records, not independent corroboration.
1.Claim 1Supported
FDA’s October 20 announcement says it approved the first generic of Climara Pro on October 19, a once-weekly combined estradiol and levonorgestrel transdermal system from Zydus Pharmaceuticals (USA).
- Scope
- U.S. FDA October 20, 2026 announcement of an October 19 approval of the first generic Climara Pro combined estradiol–levonorgestrel patch. No individual medical advice, full label, price comparison, launch confirmation or recommendation to switch.
- Evidence passage
- October 20 release opening paragraph, yesterday timing; final manufacturer-identification paragraph.
- As of
- 2026-10-21
- Limit
- Approval date differs from announcement date. No launch or inventory finding follows.
Retrieved 2026-10-21T10:02:00.042Z · US Food and Drug Administration
Regulatory announcement dated October 20 says approval occurred yesterday, October 19. Not a verified retail quote, coverage decision or full prescribing label.
2.Claim 2Supported
FDA describes the generic as therapeutically equivalent to Climara Pro, for women with an intact uterus, for moderate-to-severe menopausal vasomotor symptoms and prevention of postmenopausal osteoporosis.
- Scope
- U.S. FDA October 20, 2026 announcement of an October 19 approval of the first generic Climara Pro combined estradiol–levonorgestrel patch. No individual medical advice, full label, price comparison, launch confirmation or recommendation to switch.
- Evidence passage
- Therapeutic-equivalence paragraph and two indication bullets.
- As of
- 2026-10-21
- Limit
- Announcement-level indication summary, not a finding that any one patient needs treatment or should use this product.
Retrieved 2026-10-21T10:02:00.042Z · US Food and Drug Administration
Regulatory announcement dated October 20 says approval occurred yesterday, October 19. Not a verified retail quote, coverage decision or full prescribing label.
3.Claim 3Attributed
The combined estrogen–progestogen patch differs from estrogen-only patches; FDA says its progestogen component reduces the endometrial-hyperplasia risk associated with estrogen alone.
- Scope
- U.S. FDA October 20, 2026 announcement of an October 19 approval of the first generic Climara Pro combined estradiol–levonorgestrel patch. No individual medical advice, full label, price comparison, launch confirmation or recommendation to switch.
- Evidence passage
- Paragraph distinguishing the combined system from estrogen-only patches and explaining intact-uterus scope.
- As of
- 2026-10-21
- Limit
- Does not make different patches interchangeable or eliminate hormone-therapy risks.
Retrieved 2026-10-21T10:02:00.042Z · US Food and Drug Administration
Regulatory announcement dated October 20 says approval occurred yesterday, October 19. Not a verified retail quote, coverage decision or full prescribing label.
4.Claim 4Supported
FDA lists contraindications including unexplained genital bleeding, breast cancer history, estrogen-dependent cancers, clotting or arterial thromboembolic histories, certain hypersensitivities, liver disease and thrombophilic disorders.
- Scope
- U.S. FDA October 20, 2026 announcement of an October 19 approval of the first generic Climara Pro combined estradiol–levonorgestrel patch. No individual medical advice, full label, price comparison, launch confirmation or recommendation to switch.
- Evidence passage
- Contraindications paragraph beginning Climara Pro and the generic estradiol and levonorgestrel transdermal system.
- As of
- 2026-10-21
- Limit
- Summary is not the full prescribing label or an individual suitability assessment; adverse reactions also remain possible.
Retrieved 2026-10-21T10:02:00.042Z · US Food and Drug Administration
Regulatory announcement dated October 20 says approval occurred yesterday, October 19. Not a verified retail quote, coverage decision or full prescribing label.
5.Claim 5Supported
FDA directs readers to the manufacturer for availability information and gives no retail price or individual insurance-coverage finding in this announcement.
- Scope
- U.S. FDA October 20, 2026 announcement of an October 19 approval of the first generic Climara Pro combined estradiol–levonorgestrel patch. No individual medical advice, full label, price comparison, launch confirmation or recommendation to switch.
- Evidence passage
- Final substantive paragraph identifying Zydus and directing availability questions to the manufacturer; complete announcement checked for prices.
- As of
- 2026-10-21
- Limit
- No assertion that the generic is already stocked or will reduce a particular person’s bill.
Retrieved 2026-10-21T10:02:00.042Z · US Food and Drug Administration
Regulatory announcement dated October 20 says approval occurred yesterday, October 19. Not a verified retail quote, coverage decision or full prescribing label.
What remains open.
- Full current branded/generic labels, approval package, commercial launch, local stock, retail price and individual coverage not verified.
- No patient-specific benefit, safety assessment, switching recommendation or cost saving established.
A corrected original record or a dated follow-up that changes the stated scope, implementation, affected population or practical action; retain the earlier version and document the material change.
THIS STORY IN TIME
Keep the dates with the story.
- Reported development
- Evidence as of
- First retained publication
- This version published
Publication times are Central. A development date and an evidence date can differ. Missing dates remain unrecorded.